Bila Xitan Fensanpian (吡拉西坦分散片)吡拉西坦分散片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司
主要成分Active Ingredients
- 吡拉西坦Bila Xitan
药物知识说明
吡拉西坦是一种在国家药监局注册认定的药品。该药品含有吡拉西坦-e6b3f02b等成分。
该药品关联的活性成分包括：吡拉西坦Bila Xitan。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司。
您可以探索含有相同成分的其他药品：吡拉西坦-e6b3f02b成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 吡拉西坦分散片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 吡拉西坦Bila Xitan.
Manufacturers recorded for this product: 东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司.
Explore other medicines containing the same ingredient: 吡拉西坦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 吡拉西坦分散片Recorded Chinese name: 吡拉西坦分散片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 每片0.8g，30片/瓶。Recorded Chinese description: 每片0.8g，30片/瓶。
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 东北制药集团沈阳第一制药有限公司Chinese legal name: 东北制药集团沈阳第一制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20030997
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20030997
Manufacturer
Chinese legal name: 东北制药集团沈阳第一制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20030997
生产企业
东北制药集团沈阳第一制药有限公司(国产)
适应症
1.本品吡拉西坦主要用于治疗记忆和思维障碍，对于脑血管意外、脑外伤、癫痫后遗症；一氧化碳、酒精及药物中毒所引起的记忆思维障碍均有一定疗效。 2.对某些儿童智能低下及夜尿症也有一定疗效。
用法用量
1.将该片放入温水中待分散后服用，通常成人每次一片，每日三次。 2.重症可增至每次2片，每日三次。 3.儿童每公斤体重每天给40毫克，3～6周为一疗程后，维持剂量减半或遵医嘱。
不良反应
一般情况下病人对本品有很好的耐受性，个别病人服药后偶见口干，胃纳减退等，停药后症状自行消失。
禁忌
锥体外系疾病，Huntington舞蹈症者禁用本品，以免加重症状。
注意事项
肝肾功能障碍者慎用并应适当减少剂量。
贮藏
遮光、密闭保存。
规格
每片0.8g，30片/瓶。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.